MapLight Therapeutics
CompanyUnited States
MapLight Therapeutics develops one asset, in phase 2 (ML-007C-MA in psychosis associated with Alzheimer's disease). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $870M
- 2
- Trials
- 4
- Signals
Pipeline
1Combines central M1 and M4 muscarinic receptor agonism with peripheral muscarinic antagonism to limit peripheral side effects.
Phase 2, Small molecule, psychosis associated with Alzheimer's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Funding rounds and grants10
- Deals2
- People13
- Signals6
- Similar companies3